Steven Cohen X4 Pharmaceuticals, Inc Transaction History
Point72 Asset Management, L.P.
- $42.2 Billion
- Q4 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 650,000 shares of XFOR stock, worth $312,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
650,000
Previous 625,052
3.99%
Holding current value
$312,000
Previous $418,000
19.62%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding XFOR
# of Institutions
97Shares Held
99.6MCall Options Held
421KPut Options Held
80.6K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$8.12 Million3.52% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$7.19 Million0.82% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$5.12 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$3.94 Million0.0% of portfolio
-
Acorn Capital Advisors, LLC New York, NY7.31MShares$3.51 Million2.9% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $33M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...